Susana Maria Campos, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endometrial Neoplasms | 14 | 2023 | 1353 | 1.820 |
Why?
|
| Ovarian Neoplasms | 28 | 2023 | 4838 | 1.460 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 35 | 2023 | 11524 | 1.390 |
Why?
|
| Fallopian Tube Neoplasms | 10 | 2016 | 324 | 1.200 |
Why?
|
| Peritoneal Neoplasms | 13 | 2023 | 665 | 1.180 |
Why?
|
| Genital Neoplasms, Female | 7 | 2024 | 523 | 1.120 |
Why?
|
| Neoplasm Recurrence, Local | 27 | 2022 | 9239 | 0.980 |
Why?
|
| Uterine Neoplasms | 9 | 2023 | 1513 | 0.850 |
Why?
|
| Mixed Tumor, Mullerian | 5 | 2014 | 56 | 0.720 |
Why?
|
| Carcinosarcoma | 3 | 2023 | 108 | 0.700 |
Why?
|
| Uterine Cervical Neoplasms | 14 | 2023 | 2020 | 0.690 |
Why?
|
| DNA Polymerase II | 1 | 2019 | 107 | 0.650 |
Why?
|
| Carboplatin | 11 | 2022 | 801 | 0.620 |
Why?
|
| Aromatase Inhibitors | 3 | 2009 | 491 | 0.600 |
Why?
|
| Carcinoma, Endometrioid | 2 | 2023 | 271 | 0.580 |
Why?
|
| Vulvar Neoplasms | 3 | 2024 | 272 | 0.490 |
Why?
|
| Paclitaxel | 9 | 2022 | 1708 | 0.490 |
Why?
|
| Doxorubicin | 10 | 2020 | 2234 | 0.450 |
Why?
|
| Neoplasm Staging | 25 | 2020 | 11031 | 0.450 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2014 | 664 | 0.440 |
Why?
|
| Antimitotic Agents | 1 | 2012 | 30 | 0.420 |
Why?
|
| Tubulin Modulators | 1 | 2012 | 110 | 0.400 |
Why?
|
| Hematinics | 2 | 2005 | 281 | 0.390 |
Why?
|
| Breast Neoplasms | 12 | 2022 | 20822 | 0.360 |
Why?
|
| Nitriles | 4 | 2009 | 956 | 0.350 |
Why?
|
| Stomach Neoplasms | 1 | 2019 | 1333 | 0.350 |
Why?
|
| Erythropoietin | 2 | 2005 | 726 | 0.350 |
Why?
|
| Androstadienes | 2 | 2009 | 346 | 0.340 |
Why?
|
| Triazoles | 4 | 2009 | 911 | 0.340 |
Why?
|
| Antineoplastic Agents | 11 | 2021 | 13695 | 0.320 |
Why?
|
| Teratoma | 1 | 2011 | 395 | 0.320 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2014 | 2038 | 0.300 |
Why?
|
| Adenocarcinoma | 6 | 2024 | 6364 | 0.280 |
Why?
|
| Glioblastoma | 1 | 2021 | 3481 | 0.270 |
Why?
|
| Female | 84 | 2024 | 380194 | 0.270 |
Why?
|
| Pyrroles | 1 | 2012 | 1146 | 0.270 |
Why?
|
| Needs Assessment | 1 | 2012 | 1147 | 0.260 |
Why?
|
| Disease-Free Survival | 9 | 2020 | 6895 | 0.250 |
Why?
|
| Desensitization, Immunologic | 3 | 2016 | 483 | 0.250 |
Why?
|
| Anemia | 2 | 2005 | 1506 | 0.240 |
Why?
|
| Sulfonamides | 1 | 2014 | 1938 | 0.240 |
Why?
|
| Quinazolines | 3 | 2022 | 1356 | 0.240 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2021 | 2455 | 0.240 |
Why?
|
| Indoles | 1 | 2012 | 1839 | 0.240 |
Why?
|
| Drug Administration Schedule | 12 | 2020 | 4933 | 0.230 |
Why?
|
| Neoplasms | 7 | 2022 | 21683 | 0.220 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2003 | 61 | 0.220 |
Why?
|
| Enzyme Inhibitors | 2 | 2004 | 3798 | 0.210 |
Why?
|
| Morpholines | 1 | 2005 | 571 | 0.210 |
Why?
|
| Humans | 94 | 2024 | 744343 | 0.210 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2020 | 5535 | 0.210 |
Why?
|
| Hemoglobins | 2 | 2005 | 1534 | 0.210 |
Why?
|
| Survivors | 2 | 2012 | 2291 | 0.210 |
Why?
|
| Sexual Behavior | 1 | 2012 | 2057 | 0.210 |
Why?
|
| Pyrazoles | 3 | 2021 | 1972 | 0.200 |
Why?
|
| Pyrimidines | 1 | 2014 | 2942 | 0.200 |
Why?
|
| Endodermal Sinus Tumor | 1 | 2022 | 47 | 0.200 |
Why?
|
| Pyrimidinones | 2 | 2021 | 371 | 0.200 |
Why?
|
| Cyclodextrins | 1 | 2021 | 57 | 0.200 |
Why?
|
| Middle Aged | 48 | 2023 | 213383 | 0.200 |
Why?
|
| Pancreatic Neoplasms | 1 | 2019 | 5256 | 0.200 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2023 | 221 | 0.200 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2005 | 692 | 0.190 |
Why?
|
| Aged | 45 | 2022 | 163280 | 0.190 |
Why?
|
| Receptor, erbB-2 | 7 | 2022 | 2416 | 0.190 |
Why?
|
| Postmenopause | 3 | 2009 | 2461 | 0.190 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2017 | 4034 | 0.190 |
Why?
|
| Isoindoles | 1 | 2020 | 41 | 0.190 |
Why?
|
| Drug Hypersensitivity | 3 | 2016 | 884 | 0.190 |
Why?
|
| Anthracyclines | 1 | 2003 | 288 | 0.190 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2005 | 1524 | 0.190 |
Why?
|
| Cystadenocarcinoma, Serous | 3 | 2021 | 450 | 0.180 |
Why?
|
| DNA Mismatch Repair | 2 | 2022 | 426 | 0.180 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2020 | 5172 | 0.170 |
Why?
|
| Medical Oncology | 5 | 2019 | 2265 | 0.160 |
Why?
|
| Maximum Tolerated Dose | 4 | 2020 | 892 | 0.160 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2012 | 3479 | 0.160 |
Why?
|
| Omentum | 1 | 2019 | 170 | 0.160 |
Why?
|
| Antibodies, Monoclonal | 8 | 2022 | 9274 | 0.160 |
Why?
|
| Treatment Outcome | 23 | 2022 | 63114 | 0.160 |
Why?
|
| Camptothecin | 1 | 2021 | 576 | 0.160 |
Why?
|
| Sarcoma | 3 | 2021 | 1897 | 0.160 |
Why?
|
| Vinblastine | 4 | 2020 | 502 | 0.150 |
Why?
|
| Neoplasms, Glandular and Epithelial | 2 | 2013 | 484 | 0.150 |
Why?
|
| Deoxycytidine | 5 | 2015 | 826 | 0.140 |
Why?
|
| Hospice Care | 1 | 2023 | 672 | 0.140 |
Why?
|
| Neoplasm Proteins | 1 | 2008 | 3703 | 0.140 |
Why?
|
| Papillomavirus Infections | 2 | 2019 | 1587 | 0.130 |
Why?
|
| Cell Cycle Proteins | 2 | 2021 | 3462 | 0.130 |
Why?
|
| Adult | 37 | 2023 | 214055 | 0.130 |
Why?
|
| Benzamides | 1 | 2020 | 1379 | 0.130 |
Why?
|
| Telemedicine | 2 | 2023 | 2872 | 0.130 |
Why?
|
| Hernia, Ventral | 1 | 1997 | 176 | 0.120 |
Why?
|
| Sirolimus | 1 | 2022 | 1564 | 0.120 |
Why?
|
| Epoetin Alfa | 2 | 2005 | 83 | 0.120 |
Why?
|
| Rectal Neoplasms | 3 | 2008 | 1206 | 0.120 |
Why?
|
| Organoplatinum Compounds | 2 | 2013 | 408 | 0.120 |
Why?
|
| Ligands | 3 | 2022 | 3282 | 0.110 |
Why?
|
| Injections, Intraperitoneal | 2 | 2012 | 425 | 0.110 |
Why?
|
| Piperidines | 2 | 2020 | 1602 | 0.110 |
Why?
|
| Pilot Projects | 5 | 2023 | 8324 | 0.110 |
Why?
|
| Neoadjuvant Therapy | 4 | 2013 | 2728 | 0.110 |
Why?
|
| Cisplatin | 3 | 2020 | 1662 | 0.110 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2022 | 2109 | 0.110 |
Why?
|
| Guidelines as Topic | 3 | 2020 | 1405 | 0.110 |
Why?
|
| Indazoles | 1 | 2014 | 289 | 0.110 |
Why?
|
| Taxoids | 1 | 2015 | 666 | 0.110 |
Why?
|
| Terminal Care | 1 | 2023 | 1694 | 0.100 |
Why?
|
| Infusions, Intravenous | 5 | 2020 | 2274 | 0.100 |
Why?
|
| Uterine Cervical Dysplasia | 2 | 2004 | 387 | 0.090 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2014 | 506 | 0.090 |
Why?
|
| Recombinant Proteins | 3 | 2005 | 6622 | 0.090 |
Why?
|
| Combined Modality Therapy | 8 | 2013 | 8642 | 0.090 |
Why?
|
| Phthalazines | 2 | 2022 | 363 | 0.090 |
Why?
|
| Aged, 80 and over | 11 | 2021 | 57776 | 0.080 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 3597 | 0.080 |
Why?
|
| Feasibility Studies | 3 | 2021 | 5078 | 0.080 |
Why?
|
| Liposomes | 2 | 2003 | 759 | 0.080 |
Why?
|
| HSP90 Heat-Shock Proteins | 2 | 2021 | 434 | 0.080 |
Why?
|
| Prognosis | 9 | 2016 | 29063 | 0.080 |
Why?
|
| Genes, erbB-1 | 1 | 2008 | 161 | 0.080 |
Why?
|
| Disease Progression | 6 | 2022 | 13284 | 0.080 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 2006 | 648 | 0.080 |
Why?
|
| Receptor, erbB-3 | 1 | 2008 | 142 | 0.080 |
Why?
|
| Survival Rate | 6 | 2017 | 12788 | 0.080 |
Why?
|
| Dioxoles | 1 | 2007 | 104 | 0.070 |
Why?
|
| Topotecan | 5 | 2006 | 137 | 0.070 |
Why?
|
| Retrospective Studies | 8 | 2022 | 77449 | 0.070 |
Why?
|
| Tetrahydroisoquinolines | 1 | 2007 | 91 | 0.070 |
Why?
|
| Cohort Studies | 5 | 2019 | 40561 | 0.070 |
Why?
|
| Brachytherapy | 3 | 2019 | 1248 | 0.070 |
Why?
|
| Receptors, Estrogen | 3 | 2022 | 2187 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2020 | 10943 | 0.070 |
Why?
|
| Oncogene Proteins v-erbB | 1 | 2005 | 17 | 0.070 |
Why?
|
| Immunotherapy | 2 | 2020 | 4445 | 0.070 |
Why?
|
| Administration, Oral | 3 | 2012 | 3913 | 0.070 |
Why?
|
| Filgrastim | 1 | 2005 | 133 | 0.060 |
Why?
|
| Clinical Trials as Topic | 4 | 2013 | 7913 | 0.060 |
Why?
|
| Exercise | 1 | 2021 | 5615 | 0.060 |
Why?
|
| Megestrol Acetate | 1 | 2004 | 18 | 0.060 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2005 | 257 | 0.060 |
Why?
|
| Hysterectomy | 3 | 2019 | 927 | 0.060 |
Why?
|
| Paget Disease, Extramammary | 1 | 2024 | 45 | 0.060 |
Why?
|
| Salvage Therapy | 1 | 2010 | 1275 | 0.060 |
Why?
|
| Diagnostic Imaging | 1 | 2017 | 3507 | 0.060 |
Why?
|
| Daunorubicin | 1 | 2003 | 158 | 0.050 |
Why?
|
| Ribose | 1 | 2022 | 68 | 0.050 |
Why?
|
| Adenovirus E1B Proteins | 1 | 2002 | 15 | 0.050 |
Why?
|
| Diphosphates | 1 | 2022 | 88 | 0.050 |
Why?
|
| Pregnancy Complications, Neoplastic | 3 | 2010 | 255 | 0.050 |
Why?
|
| Radiography | 2 | 2011 | 7023 | 0.050 |
Why?
|
| Risk | 1 | 2014 | 9687 | 0.050 |
Why?
|
| Interdisciplinary Communication | 1 | 2007 | 950 | 0.050 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2008 | 1676 | 0.050 |
Why?
|
| Interprofessional Relations | 1 | 2007 | 1011 | 0.050 |
Why?
|
| Progestins | 1 | 2003 | 306 | 0.050 |
Why?
|
| Skin Tests | 2 | 2015 | 613 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2022 | 462 | 0.050 |
Why?
|
| Boston | 2 | 2010 | 9313 | 0.040 |
Why?
|
| Quality of Life | 4 | 2023 | 12804 | 0.040 |
Why?
|
| Nausea | 1 | 2003 | 673 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2012 | 4554 | 0.040 |
Why?
|
| Diamines | 1 | 2019 | 59 | 0.040 |
Why?
|
| Time Factors | 4 | 2010 | 40075 | 0.040 |
Why?
|
| Tamoxifen | 1 | 2004 | 981 | 0.040 |
Why?
|
| Blood Transfusion | 1 | 2005 | 1301 | 0.040 |
Why?
|
| Bleomycin | 1 | 2020 | 512 | 0.040 |
Why?
|
| Polyethylene Glycols | 2 | 2020 | 1182 | 0.040 |
Why?
|
| Alopecia | 1 | 2003 | 382 | 0.040 |
Why?
|
| Survival Analysis | 3 | 2009 | 10252 | 0.040 |
Why?
|
| Mass Screening | 3 | 2019 | 5255 | 0.040 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2020 | 404 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2019 | 6538 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 15540 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 7279 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 12245 | 0.040 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2019 | 261 | 0.040 |
Why?
|
| Cancer Vaccines | 1 | 2005 | 1023 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2008 | 3508 | 0.040 |
Why?
|
| Chromosome Deletion | 1 | 2022 | 1401 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2008 | 2219 | 0.040 |
Why?
|
| Genes, BRCA1 | 1 | 2021 | 781 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2014 | 11483 | 0.040 |
Why?
|
| Aminopterin | 1 | 2016 | 15 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2010 | 3086 | 0.040 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2003 | 1205 | 0.040 |
Why?
|
| Scalp | 1 | 1999 | 380 | 0.030 |
Why?
|
| Fatigue | 1 | 2023 | 1531 | 0.030 |
Why?
|
| Decision Trees | 2 | 2008 | 506 | 0.030 |
Why?
|
| Colposcopy | 2 | 2008 | 144 | 0.030 |
Why?
|
| Colonic Diseases | 1 | 1997 | 202 | 0.030 |
Why?
|
| Giant Cell Arteritis | 1 | 1999 | 292 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 2 | 2016 | 3616 | 0.030 |
Why?
|
| Cervix Uteri | 1 | 2019 | 590 | 0.030 |
Why?
|
| Brain | 1 | 2021 | 26385 | 0.030 |
Why?
|
| Pyridones | 1 | 2019 | 712 | 0.030 |
Why?
|
| Mutation | 1 | 2019 | 29786 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2022 | 2751 | 0.030 |
Why?
|
| Neoplasm Metastasis | 3 | 2013 | 4851 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2021 | 9959 | 0.030 |
Why?
|
| Liver Neoplasms | 1 | 2009 | 4253 | 0.030 |
Why?
|
| Heart Diseases | 2 | 2003 | 2788 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2022 | 2938 | 0.030 |
Why?
|
| Papillomaviridae | 1 | 2019 | 1119 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 1999 | 1442 | 0.030 |
Why?
|
| Hydroxamic Acids | 1 | 2015 | 494 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2016 | 2327 | 0.030 |
Why?
|
| Caregivers | 1 | 2023 | 2094 | 0.030 |
Why?
|
| Remission Induction | 1 | 2017 | 2386 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2017 | 1770 | 0.020 |
Why?
|
| Motivation | 1 | 2021 | 1971 | 0.020 |
Why?
|
| Risk Factors | 3 | 2017 | 72290 | 0.020 |
Why?
|
| Cancer Care Facilities | 1 | 2013 | 402 | 0.020 |
Why?
|
| Pregnancy | 4 | 2019 | 29144 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 2503 | 0.020 |
Why?
|
| Recurrence | 2 | 2012 | 8340 | 0.020 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2016 | 808 | 0.020 |
Why?
|
| Palliative Care | 1 | 2023 | 3493 | 0.020 |
Why?
|
| Myometrium | 1 | 2009 | 181 | 0.020 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2008 | 68 | 0.020 |
Why?
|
| Brain Neoplasms | 1 | 2009 | 8863 | 0.020 |
Why?
|
| Guanine | 1 | 2008 | 274 | 0.020 |
Why?
|
| Glutamates | 1 | 2008 | 398 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2019 | 3743 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2017 | 2616 | 0.020 |
Why?
|
| Endometrium | 1 | 2009 | 424 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2012 | 2242 | 0.020 |
Why?
|
| Male | 7 | 2020 | 350118 | 0.020 |
Why?
|
| Young Adult | 1 | 2012 | 56430 | 0.020 |
Why?
|
| Biopsy | 1 | 2017 | 6756 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 2024 | 5686 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2009 | 13102 | 0.020 |
Why?
|
| Adolescent | 2 | 2009 | 85781 | 0.020 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2013 | 1624 | 0.010 |
Why?
|
| Etoposide | 1 | 2005 | 641 | 0.010 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2003 | 59 | 0.010 |
Why?
|
| Hormone Replacement Therapy | 1 | 2009 | 745 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 2010 | 1738 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2009 | 2879 | 0.010 |
Why?
|
| Health Care Costs | 1 | 2016 | 3209 | 0.010 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2002 | 107 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 2008 | 1462 | 0.010 |
Why?
|
| Disease Management | 1 | 2013 | 2459 | 0.010 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2005 | 629 | 0.010 |
Why?
|
| Vaginal Smears | 1 | 2004 | 511 | 0.010 |
Why?
|
| Risk Assessment | 2 | 2015 | 23338 | 0.010 |
Why?
|
| Perioperative Care | 1 | 2008 | 1002 | 0.010 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2005 | 841 | 0.010 |
Why?
|
| Logistic Models | 1 | 2015 | 13408 | 0.010 |
Why?
|
| Plasmids | 1 | 2005 | 2307 | 0.010 |
Why?
|
| Algorithms | 3 | 2004 | 13881 | 0.010 |
Why?
|
| Receptors, Progesterone | 1 | 2003 | 1097 | 0.010 |
Why?
|
| Adenoviridae | 1 | 2002 | 1099 | 0.010 |
Why?
|
| Antigens, Neoplasm | 1 | 2005 | 1988 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2009 | 3610 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2019 | 23403 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2001 | 2886 | 0.010 |
Why?
|
| ROC Curve | 1 | 2003 | 3527 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2009 | 7785 | 0.010 |
Why?
|
| Necrosis | 1 | 1999 | 1643 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 39050 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 2007 | 3528 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1997 | 20129 | 0.010 |
Why?
|
| Virus Replication | 1 | 2002 | 2534 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2002 | 2948 | 0.010 |
Why?
|
| United States | 1 | 2019 | 69872 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 2002 | 3176 | 0.010 |
Why?
|
| Pyridines | 1 | 2002 | 2825 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 35421 | 0.010 |
Why?
|
| Cardiomyopathies | 1 | 2001 | 1912 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2012 | 53288 | 0.000 |
Why?
|
| Predictive Value of Tests | 1 | 2003 | 15076 | 0.000 |
Why?
|